Abstract

Early clinical studies using immunotherapy targeting checkpoint receptors on T cells in pancreatic cancer patients have been disappointing. Our approach has been to target the innate immune system in an effort to make the adaptive immune system more susceptible to immunotherapy. Our approaches have targeted protein kinases, innate immune receptors, the microbiome, and innate T cells.